Skip to content

KLRS KLRS Total Current Liabilities

Total Current Liabilities at other companies

Eli Lilly logo
Eli LillyLLY
$36.63B+21.8%
Merck & Co. logo
Merck & Co.MRK
$26.95B+7.0%
Amgen logo
AmgenAMGN
$24.96B+8.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$5.11B+43.2%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$37.46M-10.1%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$47.68M+25.7%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's total current liabilities?
KLRS (KLRS) reported total current liabilities of $8.08M in Q1 2026.
How has KLRS's total current liabilities changed year-over-year?
KLRS's total current liabilities increased by 13.1% year-over-year, from $7.14M to $8.08M.
What is the long-term trend for KLRS's total current liabilities?
Over 4 years (2021 to 2025), KLRS's total current liabilities has grown at a -28.8% compound annual growth rate (CAGR), from $37.85M to $9.71M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.